<DOC>
	<DOCNO>NCT00991393</DOCNO>
	<brief_summary>The purpose research study shorten treatment time course patient schedule surgery sinus lift dental implant ( ) place upper front part mouth , need bone jaws thicker sinus floor support implant .</brief_summary>
	<brief_title>Sinus Augmentation With Dental Implant</brief_title>
	<detailed_description>The INFUSE® Bone Graft device approve FDA use instead use bone ( another site body ) replace miss bone jaw . INFUSE® Bone Graft commercially available make 2 part - recombinant human Bone Morphogenetic Protein-2 ( rhBMP 2 ) place absorbable collagen sponge ( ACS ) . The rhBMP-2 genetically alter protein recruit bone-forming cell surgical area change local cell bone . ACS make Type I collagen bovine ( cattle ) tendon . It help hold rhBMP-2 place act support grow bone . The sponge reabsorb time new bone form . The purpose research study shorten treatment time course patient . This post-market study design evaluate effectiveness safety INFUSE® Bone Graft , along dental implant placement sinus lift , single procedure .</detailed_description>
	<criteria>1 . Able provide write informed consent 2 . ≥ 18 year 3 . Requires receive sinus augmentation part schedule dental implantation maxillary alveolar ridge 4 . Negative urine pregnancy test patient child bear potential agreement become pregnant least 12 month surgery 5 . Able comply studyrelated procedure , include exercise good oral hygiene 6 . A prosthodontic treatment plan draft . 1 . Known hypersensitivity rhBMP2 , bovine Type I collagen component formulation 2 . Known hypersensitivity titanium 3 . Operative site area resect extant tumor 4 . Any active malignancy current treatment malignancy 5 . Active infection operative site 6 . History prior exposure rhBMP2/ACS 7 . Received fail previous sinus augmentation procedure 8 . Pathology would either compromise bone graft procedure , interfere obtain quantitative measurement postoperative computer tomography scan 9 . Significant untreated periodontal disease ( &gt; Grade 3 ) , caries , chronic inflammation oral cavity operative site 10 . Active use nicotinecontaining product , limited , smoke chew tobacco , nicotine patch , nicotine gum , etc . 11 . Insulindependent diabetic , know HgbA1c level &gt; 6.5 % 12 . History malignancy within past 5 year except basal cell squamous cell carcinoma skin 13 . Patients lactate 14 . History metabolic bone disease , exclude idiopathic osteoporosis 15 . History autoimmune disease ( e.g. , documented multiple allergy , systemic lupus erythematosus , dermatomyositis , etc . ) immunosuppressive disease ( e.g , Human Immunodeficiency Virus Acquired Immune Deficiency Syndrome ) 16 . History immune deficiency due treatment ( e.g. , radiation therapy , chemotherapy , steroid therapy ) 17 . History adverse reaction prior exposure silicone injectable collagen 18 . Treatment investigational therapy within 1 month surgical procedure plan treat investigational therapy study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Maxillary Sinus Augmentation</keyword>
	<keyword>Dental Implantation</keyword>
	<keyword>Osseointegration</keyword>
	<keyword>Bone Morphogenetic Proteins</keyword>
</DOC>